IMMUNINE Pre-Treatment Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT01128881
First received: May 7, 2010
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

The primary objective of this study is to prospectively document the exposure to IMMUNINE and to monitor FIX inhibitors over a period of approximately 20 to 50 exposure days while receiving prophylactic treatment in up to 50 previously treated patients (PTPs) aged 12-64 years and approximately 20 pediatric PTPs up to 11 years of age with severe (FIX level < 1%) or moderately severe (FIX level <= 2%) hemophilia B who are planned to enter BAX326 study 250901, provided all eligibility criteria are met.

In addition, this study will evaluate the efficacy, safety, immunogenicity, thrombogenicity, and health-related quality of life (HR QoL) of these subjects.


Condition Intervention Phase
Hemophilia B
Biological: Factor IX Concentrate (purified, virus-inactivated)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: IMMUNINE - Purified Factor IX Concentrate Virus-Inactivated: A Phase 4, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B Who Are Planned to Enter BAX 326 Study 250901 to Investigate a New Recombinant FIX Concentrate

Resource links provided by NLM:


Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Hemostatic Efficacy [ Time Frame: 28 months ] [ Designated as safety issue: No ]
    • Number of IMMUNINE infusions required to achieve adequate hemostasis for each bleeding episode
    • Overall hemostatic efficacy rating of IMMUNINE for all bleeding episodes (scale of excellent, good, fair, none)
    • Annualized bleeding rate
    • Consumption of IMMUNINE
    • Number of infusions per month and per year (prophylaxis and on-demand)
    • Weight-adjusted consumption of IMMUNINE per event (prophylaxis, on-demand), per month and per year


Enrollment: 57
Study Start Date: May 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMMUNINE Biological: Factor IX Concentrate (purified, virus-inactivated)
Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
Other Name: IMMUNINE

  Eligibility

Ages Eligible for Study:   up to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is up to 64 years old at the time of screening
  • Subject and/or legal representative has/have provided signed informed consent
  • Subject has severe (FIX level < 1%) or moderately severe (FIX level <= 2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory
  • Subject is previously treated with plasma-derived or recombinant FIX concentrate(s), cryoprecipitate or fresh frozen plasma (FFP) for approximately 100-150 exposure days (EDs) if >= 6 years old, or 20-50 EDs if < 6 years old, and is planned to enter BAX326 study 250901. The number of EDs are derived from the subject's treatment regimen and his/her bleeding pattern
  • Subject is willing to receive prophylactic treatment for the duration of the study
  • Subject is immunocompetent as evidenced by a CD4 count >= 200 cells/mm(3)
  • Subject is human immunodeficiency (HIV) negative or is HIV+ with a viral load < 200 particles/μL ~ < 400,000 copies/mL
  • Female subject of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study
  • Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

  • The subject has a detectable factor IX inhibitor at screening, with a titer >= 0.6 Bethesda Units (BU) as determined by the Nijmegen modification of the Bethesda assay in the central laboratory
  • The subject has a history of factor IX inhibitors with a titer >= 0.6 BU (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening
  • The subject has a history of allergic reaction, eg, anaphylaxis, following exposure to factor IX concentrate(s)
  • The subject has a known hypersensitivity to hamster proteins
  • The subject has evidence of a thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC)
  • The subject is scheduled for elective surgery, unless the surgery is medically required within the anticipated study period
  • The subject has an abnormal renal function (serum creatinine > 1.5 times the upper limit of normal)
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) exceeding the upper limit of normal (ULN), hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices
  • The subject has active hepatic disease with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >= 5 times the upper limit of normal. During the study, subjects with chronic hepatitis B or C may have fluctuations of up to 5 times the upper limit of normal but will not require discontinuation.
  • The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia B
  • The subject's platelet count is < 100,000/mL
  • The subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject's safety or compliance
  • The subject is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug other than anti-retroviral chemotherapy (eg, α-interferon, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day)
  • The subject is unwilling to consider further participation in BAX 326 (rFIX) pivotal study 250901 or BAX 326 pediatric study
  • The subject has participated in another investigational study within 30 days of enrollment or is scheduled to participate in another clinical study involving an investigational product (IP) or investigational device during the course of this study
  • The subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01128881

Locations
Argentina
Hospital JR Vidal (Servicio de Hemotologie - Area de Investiagacion
Corrientes Capital, Argentina, 3400
Instituto de Hemofilia y Medicina Clinica Rubén Dávoli
Rosario, Argentina, 2000
Brazil
Hospital do apoio de Brasilia
Distrito Federal, Brazil, 72620-000
UNIFESP - Universidade Estadual de Sáo Paulo
Sáo Paulo, Brazil, 040024-002
Bulgaria
Specialized Haematological Hospital "Joan Pavel"
Sofia, Bulgaria, 1233
Chile
Hospital Dr. Sotero del Rio
Santiago, Chile
Hospital san José, Centro de Hemofilia
Santiago, Chile
Colombia
Centro Medico Imbanaco
Cali, Colombia
Czech Republic
Klinika detske hematologie a onkologie UK
Prague, Czech Republic, 150 06
Poland
Hematology and Transplantology Clinic, University Clinic Centre - Medical University Hospital
Gdansk, Poland, 80-952
Medical College of the Jagiellonian University
Krakow, Poland, 31-501
Medical University Lodz, Department of Hematology
Lodz, Poland, 93-510
Institute of Haematology and Transfusion
Warsaw, Poland, 02-776
Romania
Prof. Dr. C. T. Nicolau National Institute for Transfusional Hematology
Bucharest, Romania, 11156
Louis Turcanu Emergency Clinical Children´s Hospital
Timisoara, Romania
Russian Federation
Hematology Research Center RAMS, Department of Hemophilia and Other Coagulopathies
Moscow, Russian Federation, 125157
Republican Center for Hemophilia Treatment, Outpatient Clinic No. 37
St. Petersburg, Russian Federation, 195213
Ukraine
State Institution "Institute of Blood Pathology and Transfusion Medicine of Academy of Medical Sciences of Ukraine"
Lviv, Ukraine, 79044
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Study Director: Brigitt Abbuehl, MD Baxter Healthcare Corporation
  More Information

No publications provided

Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01128881     History of Changes
Other Study ID Numbers: 050901, 2009-016719-39
Study First Received: May 7, 2010
Last Updated: January 28, 2013
Health Authority: Bulgaria: Bulgarian Drug Agency
Czech Republic: State Institute for Drug Control
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Russia: FSI Scientific Center of Expertise of Medical Application
Ukraine: State Pharmacological Center - Ministry of Health
Brazil: ANVISA Agencia Nacional de Vigilance Sanitaria
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Chile: Instituto de Salud Pública de Chile

Additional relevant MeSH terms:
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on October 01, 2014